Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators

Meng SHANG; Xiaolong GAO; Xiaohui KUANG; Xi ZHANG; Jin ZHANG; Lilin WANG

doi:10.12259/j.issn.2095-610X.S20231109

Volume 44 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(11): 63-69

Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators[J]. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109

Citation:

Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators[J]. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109

Citation:

Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators[J]. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109

PDF( 643 KB)

Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators

doi: 10.12259/j.issn.2095-610X.S20231109

Dept. of Cardiology，The Affiliated Hospital of Kunming University of Science and Technology/The 1st People’s Hospital of Yunnan Province，Kunming Yunnan 650032，China

Received Date: 2022-08-22
Available Online: 2023-11-09
Publish Date: 2023-11-30

Abstract

Abstract

Objectives To investigate the effects of sacubitril/valsartan （S/V） on cardiac function and ventricular arrhythmias in patients with chronic heart failure with reduced ejection fraction（HFrEF）who underwent primary prevention of sudden cardiac death （SCD） after implantation of an implantable cardioverter defibrillator （ICD）. Methods HFrEF patients who were hospitalized in the Cardiovascular Department of the First People’ s Hospital of Yunnan Province from September 2017 to December 2022 and received S/V treatment and ICD implantation for primary prevention of SCD were included. ① We calculated the S/V dose of patients at 12 months of follow-up, as well as cardiac ultrasound indicators （LVEF, LVEDD, LAD） at 3, 6, and 12 months of treatment; ② ICD was used to record ventricular arrhythmia events and treatment status, dynamic electro-cardiogram indicators: average number of ventricular premature beats per hour, standard deviation （SDNN） of all sinus rhythm RR intervals, and corrected average QT interval （QTc）. Results A total of 56 patients were included. （1） At one-year follow-up, the average medication dose for S/V in all patients was 94.6 mg bid. （2） Following up for 3 months, LVEF, LVEDD, and LAD improved compared to before treatment （P < 0.05）; LVEF, LVEDD, and LAD improved after 6 months of follow-up compared to 3 months of treatment （P < 0.05）; LVEF, LVEDD, and LAD improved after 12 months of follow-up compared to 6 months of treatment （P < 0.05）. （3） Compared with 1-6 months of follow-up, the incidence of VT/VF, NSVT and monitored ventricular brachytherapy decreased during 7-12 months of follow-up （P < 0.05）.（4） Compared with before treatment, SDNN increased from （94.38±26.42）ms to （102.23±20.36）ms and average QTc decreased from （441.92±10.64）ms to （411.46±6.00）ms during 1-year follow-up（P < 0.05）. Conclusions （1） For HFrEF patients implanted with ICD for primary prevention of SCD, their cardiac structure and function was continued to improve within one year of receiving S/V treatment; （2） S/V reduced the occurrence of ventricular arrhythmias during the follow-up period of this study.
- Chronic Heart failure,
- Implantable cardioverter defibrillator,
- Sacubitril/Valsartan,
- Cardiac function,
- Ventricular arrhythmia

FullText(HTML)

References(27)

References

[1]	Wang H,Chai K,Du M,et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis[J]. Circ Heart Fail,2021,14(10):e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406
[2]	Murphy S P, Ibrahim N E, Januzzi J L Jr. Heart failure with reduced ejection fraction: A review. [J] JAMA, 2020 , 324（5）: 488-504.
[3]	Tsao C W,Lyass A,Enserro D,et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction[J]. JACC Heart Fail,2018,6(8):678-685. doi: 10.1016/j.jchf.2018.03.006
[4]	McMurray J J,Packer M,Desai A S,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004. doi: 10.1056/NEJMoa1409077
[5]	Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail,2022,28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010
[6]	Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082. doi: 10.1007/s00392-019-01440-y
[7]	Curtain J P,Jackson A M,Shen L,et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF[J]. Eur J Heart Fail,2022,24(3):551-561. doi: 10.1002/ejhf.2419
[8]	张常莹,刘晓宇,李晓燕,等. 沙库巴曲缬沙坦对植入了心脏除颤器的心力衰竭患者室性心律失常发生的影响[J]. 中国心脏起搏与心电生理杂志,2021,35(04):305-309. doi: 10.13333/j.cnki.cjcpe.2021.04.005
[9]	El-Battrawy I,Pilsinger C,Liebe V,et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients[J]. J Clin Med,2019,8(10):1582. doi: 10.3390/jcm8101582
[10]	Vicent L,Juárez M,Martín I,et al. Ventricular arrhythmic storm after initiating sacubitril/valsartan[J]. Cardiology,2018,139(2):119-123. doi: 10.1159/000486410
[11]	Vicent L,Méndez-Zurita F,Viñolas X,et al. Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation[J]. Heart Vessels,2020,35(1):136-142. doi: 10.1007/s00380-019-01454-6
[12]	Vicent L,Martínez-Sellés M. Can sacubitril/valsartan have a proarrhythmic effect in some high-risk patients?[J]. Cardiology,2019,143(1):34-35.
[13]	Yancy C W,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail,2017,23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014
[14]	Hubers S A,Brown N J. Combined angiotensin receptor antagonism and neprilysininhibition[J]. Circulation,2016,133(11):1115-1124. doi: 10.1161/CIRCULATIONAHA.115.018622
[15]	Levine Y C,Rosenberg M A,Mittleman M,et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias[J]. Heart Rhythm,2014,11(7):1109-1116. doi: 10.1016/j.hrthm.2014.04.024
[16]	Primessnig U,Deißler P M,Wakula P,et al. Effects of BNP and sacubitrilat/valsartan on atrial functional reserveand arrhythmogenesis in human myocardium[J]. Front Cardiovasc Med,2022,9:859014. doi: 10.3389/fcvm.2022.859014
[17]	Wang Z,Taylor L K,Denney W D,et al. Initiation of ventricular extrasystoles by myocardial stretch in chronically dilated and failing canine left ventricle[J]. Circulation,1994,90(4):2022-2031. doi: 10.1161/01.CIR.90.4.2022
[18]	Sarrias A,Bayes-Genis A. Is sacubitril/valsartan (Also) an antiarrhythmic drug?[J]. Circulation,2018,138(6):551-553. doi: 10.1161/CIRCULATIONAHA.118.034755
[19]	Eiringhaus J,Wünsche C M,Tirilomis P,et al. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca²⁺ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail,2020,7(5):2992-3002. doi: 10.1002/ehf2.12918
[20]	Zhou Y,Rui S,Tang S,et al. Exploration ofmechanisms of sacubitril/ valsartan in the treatment of cardiac arrhythmias using a network pharmacology approach[J]. Front Cardiovasc Med,2022,9:829484. doi: 10.3389/fcvm.2022.829484
[21]	Herring M P,Jacob M L,Suveg C,et al. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: A randomized controlled trial[J]. Psychother Psychosom,2012,81(1):21-28. doi: 10.1159/000327898
[22]	Bardy G H,Lee K L,Mark D B,et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure[J]. N Engl J Med,2005,352(3):225-237. doi: 10.1056/NEJMoa043399
[23]	Al-Zaiti S S,Pietrasik G,Carey M G,et al. The role of heart rate variability,heart rate turbulence,and deceleration capacity in predicting cause-specific mortality in chronic heart failure[J]. J Electrocardiol,2019,52:70-74. doi: 10.1016/j.jelectrocard.2018.11.006
[24]	Turrini P,Corrado D,Basso C,et al. Dispersion of ventricular depolarization- repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy[J]. Circulation,2001,103(25):3075-3080. doi: 10.1161/01.CIR.103.25.3075
[25]	Okin P M,Devereux R B,Howard B V,et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study[J]. Circulation,2000,101(1):61-66. doi: 10.1161/01.CIR.101.1.61
[26]	Monzo L,Gaudio C,Cicogna F,et al. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience[J]. Eur Rev Med Pharmacol Sci,2021,25(18):5690-5700.
[27]	Guerra F,Ammendola E,Ziacchi M,et al. Effect of sacubitril/valsartan on left ventricular ejection fraction and on the potential indication for implantable cardioverter defibrillator in primary prevention: the SAVE-ICD study[J]. Eur J Clin Pharmacol,2021,77(12):1835-1842. doi: 10.1007/s00228-021-03189-8

Relative Articles(20)

Relative Articles

[1]	Yan QIU, Yinli WANG, Mengmeng YANG, Liangmin GUO, Longhui YUAN. Association between MPV，PDW，PCT and Cardiac Function in Patients with Pulmonary Hypertension. Journal of Kunming Medical University, 2023, 44(12): 121-126. doi: 10.12259/j.issn.2095-610X.S20231219
[2]	Ming JIN, Mei CEN, Lijing ZHAO. Impact of Path-based Symptom Management Education Driven by Multidisciplinary Teams on The Quality of Life of Patients with Chronic Heart Failure. Journal of Kunming Medical University, 2022, 43(11): 185-192. doi: 10.12259/j.issn.2095-610X.S20221125
[3]	Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117
[4]	Feipeng WU, Xiandong ZHENG, Qiyan WU, Liju HONG, Lei YUE, Rui YANG, Dandan CHEN, Youjun ZHOU. Diagnostic Value of Gated Myocardial Perfusion Imaging Combined with NT-proBNP in Chronic Heart Failure. Journal of Kunming Medical University, 2022, 43(5): 133-139. doi: 10.12259/j.issn.2095-610X.S20220511
[5]	Hairu WANG, Pinghui ZHU, Jun WANG. Effect Evaluation of Exercise Rehabilitation on Patients with Chronic Heart Failure. Journal of Kunming Medical University, 2022, 43(6): 110-116. doi: 10.12259/j.issn.2095-610X.S20220617
[6]	Mei CEN, Ming JIN. Effect of Optimal Care + Volume Self-management on Quality of Life in Patients with Chronic Heart Failure. Journal of Kunming Medical University, 2021, 42(12): 177-182. doi: 10.12259/j.issn.2095-610X.S20211243
[7]	Hai-ping ZHANG, Shu-juan YANG, Li-xia YANG, Zhao-juan RUAN, Rui-wei GUO. Effect of Hyperhomocysteinemia on Cardiac Function and Mortality of Patients with Acute Myocardial Infarction Concomitant Hypertension underwent Primary Percutaneous Coronary Intervention after 6 Months. Journal of Kunming Medical University, 2021, 42(3): 73-78. doi: 10.12259/j.issn.2095-610X.S20210319
[8]	Zhong FANG, Xiao-dong XU, Li-hua WANG, Ying ZHANG, Chao MA. Prognostic Value of eGFR and NT-proBNP in Patients with Chronic Heart Failure Complicated with Atrial Fibrillation. Journal of Kunming Medical University, 2021, 42(11): 111-116. doi: 10.12259/j.issn.2095-610X.S20211120
[9]	Wei-wen WANG, De-xia LI, Jie ZHANG, Lin LI. Correlation Between Serum Soluble ST2 and Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Kunming Medical University, 2021, 42(8): 71-77. doi: 10.12259/j.issn.2095-610X.S20210813
[10]	Mei CEN, Dan-dan YUAN, Ming JIN, Xue-lian LIU, Wei-wei SHANG. Effect of Cardiac Exercise Rehabilitation on Cardiac Function and Quality of Life in Patients with Hypertensive Heart Disease Complicated with Heart Failure. Journal of Kunming Medical University, 2021, 42(5): 107-113. doi: 10.12259/j.issn.2095-610X.S20210520
[11]	Li Jie , Zhang Shi Ming , Yang Shu Lian . . Journal of Kunming Medical University, 2020, 41(01): 31-36.
[12]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[13]	Zhu Guo Fu , Quan Qiang , Wu Li Yong , Ruan Zhi Min , Zhang Ming Guo , Chu Tian Shu . . Journal of Kunming Medical University, 2019, 40(07): 56-61.
[14]	Zhao Xin Mei , Li Jun Mei , Yang Ju Hua , Zhao Cun Na , Zhang Pei , Huang Xiao , Wang Xiao Yan , Li Hai , Zhang Yuan Fei . . Journal of Kunming Medical University, 2019, 40(05): 144-148.
[15]	Du Zi Hong , Sun Yong . Evaluation of Arterial Elasticity, Left Ventricular Function and Correlation by 256-slice Spiral CT in Patients with Aortic Dissection. Journal of Kunming Medical University, 2018, 39(05): 50-55.
[16]	Cai Ren Hui , Zhao Xin Xiang . Detection of Myocardial Scar after Myocardial Infarction by DE-MRI and Its Relationship with Ventricular Arrhythmias. Journal of Kunming Medical University, 2016, 37(12): 127-130.
[17]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[18]	Wang Yu . . Journal of Kunming Medical University,
[19]	Hao Ying Lu . . Journal of Kunming Medical University,
[20]	. Clinical Observation on the Therapeutic Effects of Trimetazidine on Chronic Myocardia Infarction with Refractory Heart Failure. Journal of Kunming Medical University,